A practical reference on Synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also dissolves in common polar solvents |
| Storage temperature | Minus 20 degrees Celsius or lower | Applies to dry powder, desiccated and dark |
| Typical analytical methods | Reversed-phase HPLC and mass spectrometry | Used together for purity and identity |
| Primary degradation route | Hydrolysis and aggregation | No cysteine present, so disulfide formation is unlikely |
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Blood tests conducted by WADA at the 2004 Olympic Games in Athens, Greece, targeted primarily HGH. Use of the drug for performance enhancement is not currently approved by the FDA. GH has been studied for use in raising livestock more efficiently in industrial agriculture and several efforts have been made to obtain governmental approval to use GH in livestock production. These uses have been controversial. In the United States, the only FDA-approved use of GH for livestock is the use of a cow-specific form of GH called bovine somatotropin for increasing milk production in dairy cows. Retailers are permitted to label containers of milk as produced with or without bovine somatotropin.
In January 2025, President Donald Trump signed an executive order demanding that various drug cartels and criminal organizations (Sinaloa Cartel, Gulf Cartel, La Nueva Familia Michoacana, Jalisco New Generation Cartel, Northeast Cartel, United Cartels, Tren de Aragua and Mara Salvatrucha) be added to the list of Foreign Terrorist Organizations and Specially Designated Global Terrorists, which was officially enacted on 20 February, 2025, making such groups officially Foreign Terrorist Organizations. Similarly, Canada has also joined in designating drug cartels as Foreign Terrorist Organizations. Also, in the same year, the United States similarly designated and added the Los Lobos and Los Choneros gangs to the list of foreign terrorist organizations. On October 1, 2025, in the context of Operation Southern Spear and the US naval deployment in the Caribbean, President Donald Trump formally declared that the US is engaged in a "non-international armed conflict" with "unlawful combatants" associated with drug cartels operating in the Caribbean. This legal shift enabled operations such as the recent Operation Absolute Resolve on January 3, 2026, in which US special forces captured former Venezuelan leader Nicolás Maduro in Caracas on charges of narco-terrorism.
== Biomarker == Fragments derived from the ANP precursor, including the signal peptide, NT-ProANP (N-terminal pro-ANP) and ANP, have been detected in human blood. ANP (28 residues long) is the active hormone while NT-proANP (98 residues) is the remaining part of proANP after cleavage by corin. ANP and associated peptides are used as biomarkers for cardiovascular diseases such as stroke, coronary artery disease, myocardial infarction and heart failure. A part of NT-proANP called mid-regional pro-atrial natriuretic peptide (MR-proANP) is a highly sensitive biomarker in heart failure. MR-proANP levels below 120 pmol/L can be used to effectively rule out acute heart failure. MR-proANP is measured using antibodies that bind to two consecutive parts of NT-proANP, residue number 53–72 and 73–90. In contrast, traditional NT-proANP measurement use antibodies that bind to the N-terminal of NT-proANP. In either case, antibodies are only able to determine the amount of peptides matching their epitope fragments. They largely cannot differentiate between a cleaved part (NT-proANP, ANP) and the uncleaved precursor (proANP). Large amounts of ANP secretion has been noted to cause electrolyte disturbances (hyponatremia) and polyuria. These indications can be a marker of a large atrial myxoma.
Sources: en.wikipedia.org
=== Medical illness === Cushing's syndrome (a condition in which the body contains excess amounts of cortisol) may also influence childhood obesity. Researchers analyzed two isoforms (proteins that have the same purpose as other proteins, but are programmed by different genes) in the cells of 16 adults undergoing abdominal surgery. They discovered that one type of isoform created oxo-reductase activity (the alteration of cortisone to cortisol) and this activity increased 127.5 pmol mg sup when the other type of isoform was treated with cortisol and insulin. The activity of the cortisol and insulin can possibly activate Cushing's syndrome. Hypothyroidism is a hormonal cause of obesity, but it does not significantly affect obese people who have it more than obese people who do not have it. In a comparison of 108 obese patients with hypothyroidism to 131 obese patients without hypothyroidism, researchers discovered that those with hypothyroidism had only 0.077 points more on the caloric intake scale than did those without hypothyroidism.
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by failure of peroxisomal fatty acid beta oxidation which results in the accumulation of very long chain fatty acids in tissues throughout the body. The most severely affected tissues are the myelin in the central nervous system, the adrenal cortex, and the Leydig cells in the testes. The long chain fatty acid buildup causes damage to the myelin sheath of the neurons of the brain, resulting in seizures and hyperactivity. Other symptoms include problems in speaking, listening, and understanding verbal instructions. Clinically, ALD presents as a heterogeneous disorder, showing several distinct phenotypes, and no clear pattern of genotype–phenotype correlation. As an X-linked disorder, ALD presents more frequently and severely in males; however, approximately 80% of heterozygote females show some symptoms later in life. Approximately one third of male ALD patients will present with the childhood cerebral form of the disease, which is the most severe form. It is characterized by normal development in early childhood, followed by rapid degeneration to a vegetative state. The other forms of ALD vary in timing of onset and in clinical severity, ranging from adrenal insufficiency alone to progressive paraparesis in early adulthood. ALD is caused by mutations in ABCD1, a gene located on the X chromosome that codes for ALD, a peroxisomal membrane transporter protein. The exact mechanism of the pathogenesis of the various forms of ALD is not known.
The New Zealand-founded and California-based Rocket Lab had recently acquired the Arizona company Geost, which is involved in the Golden Dome project. Russia: Russian Foreign Ministry spokeswoman Maria Zakharova said "the United States' Golden Dome project undermines the foundations of strategic stability as it involves the creation of a global missile defense system." On 8 May 2025, China and Russia made a joint statement criticizing the proposal's rejection of the "inseparable interrelationship between strategic offensive arms and strategic defensive arms", its "left-of-launch" capabilities, and its "orbital deployment of interception systems". On 21 May 2025, Press Secretary Dmitry Peskov instead stated that the plan was a "sovereign matter" for the US, and that the legal framework of defunct US-Russia nuclear arms treaties "must be recreated both in the interests of our two countries and in the interests of security throughout the planet". North Korea: On 27 May 2025, North Korea's Ministry of Foreign Affairs criticized the proposal as representing "an outer space nuclear war scenario". It denounced "undisguised moves for space militarization" and argued regional stability requires "the symmetry of the matchless power".
Sources: en.wikipedia.org
== Biosynthesis == Apigenin is biosynthetically derived from the general phenylpropanoid pathway and the flavone synthesis pathway. The phenylpropanoid pathway starts from the aromatic amino acids L-phenylalanine or L-tyrosine, both products of the Shikimate pathway. When starting from L-phenylalanine, first the amino acid is non-oxidatively deaminated by phenylalanine ammonia lyase to make cinnamate, followed by oxidation at the para position by cinnamate 4-hydroxylase to produce p-coumarate. As L-tyrosine is already oxidized at the para position, it skips this oxidation and is simply deaminated by tyrosine ammonia lyase to arrive at p-coumarate. To complete the general phenylpropanoid pathway, 4-coumarate CoA ligase substitutes coenzyme A at the carboxy group of p-coumarate. Entering the flavone synthesis pathway, the type III polyketide synthase enzyme chalcone synthase uses consecutive condensations of three equivalents of malonyl-CoA followed by aromatization to convert p-coumaroyl-CoA to chalcone. Chalcone isomerase then isomerizes the product to close the pyrone ring to make naringenin. Finally, a flavanone synthase enzyme oxidizes naringenin to apigenin. Two types of flavone synthase (FNS) have been described; FNS I, a soluble enzyme that uses 2-oxogluturate, Fe2+, and ascorbate as cofactors and FNS II, a membrane bound, NADPH dependent cytochrome p450 monooxygenase.
Vitamin E does not improve established liver fibrosis in those with MASLD, but seems to improve certain markers of liver function and reduce inflammation and fattiness of the liver in some people with MASLD. The Asia-Pacific Work Group advises that Vitamin E may improve liver condition and aminotransferase levels, but only in adults without diabetes or cirrhosis who have MASH. The NICE guidelines recommend Vitamin E as an option for children and adults with MASFLD with advanced liver fibrosis, regardless of whether the person has diabetes mellitus.
N-Acetyl-γ-aminobutyric acid (N-acetyl-GABA), also known as N-acetyl-4-aminobutyric acid, is a metabolic intermediate in the biosynthesis of γ-aminobutyric acid (GABA) from putrescine. Other intermediates in this pathway include N-acetylputrescine and N-acetyl-γ-aminobutyraldehyde (N-acetyl-GABAL or N-acetyl-GABA aldehyde). Enzymes mediating the transformations in this pathway include putrescine acetyltransferase (PAT), monoamine oxidase B (MAO-B), aldehyde dehydrogenase (ALDH), and an unknown deacetylase enzyme. The pathway is a minor pathway in GABA synthesis compared to the main pathway in which GABA is synthesized from glutamate. However, the pathway has been found to have an important physiological role in the brain, for instance in the production of GABA in the striatum and resultant inhibition of dopaminergic neurons in this brain area.
== Early life == Ada Esther Lifshitz was born in the Geula quarter of Jerusalem on 22 June 1939. Her parents, Hillel and Esther Lifshitz, were Zionist Jews who had immigrated to the British Mandate of Palestine (now Israel) from Zduńska Wola, Poland, in 1933 before the establishment of Israel. Her father was a rabbi and came from a rabbinical family. They settled in Jerusalem and ran a grocery store, but found it difficult to make ends meet while also sharing a small apartment space to live in. Despite her family's poverty, her parents sent her to school in the upscale Beit HaKerem neighborhood to assure her a good education. When her father died at the age of 42, the family moved to Tel Aviv. Yonath assisted her mother in bringing income by babysitting or tutoring children after her father's death.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.
Cold, dry, and dark conditions are standard, typically at or below minus twenty degrees Celsius for long-term holding. Vials are usually warmed to room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is generally avoided.
This depends on pH, buffer, and concentration, with acidic conditions often reported as more favorable. Hydrolysis accelerates at room temperature, so solutions are commonly prepared fresh or stored frozen in single-use aliquots. No single shelf life applies across formulations.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.